Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals Limited has announced the issuance of new ordinary fully paid securities, totaling 210,000 shares, on two separate dates in May 2025. This move is part of the company’s strategy to manage its equity and potentially strengthen its financial position, which may have implications for its market performance and stakeholder interests.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. The company targets the oncology market, providing innovative solutions for cancer diagnosis and treatment.
Average Trading Volume: 1,968,807
Technical Sentiment Signal: Buy
Current Market Cap: A$8.64B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.